Development of a nanoparticle-based influenza vaccine using the PRINT® technology

Galloway, Ashley L.; Murphy, Andrew; DeSimone, Joseph M.; Di, Jie; Herrmann, Jennifer; Hunter, Michael E.; Kindig, Jeffrey P.; Malinoski, Frank; Rumley, Megan A.; Stoltz, Daria M.; Templeman, Thomas S.; Hubby, Bolyn

doi:10.1016/j.nano.2012.11.001

Cited by 80 publications

(44 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, Hemagglutinin (HA) antigens in three commercial trivalent influenza vaccine (TIV), were electrostatically bound to the surface of cylindrical cationic PLGA-based NPs prepared by PRINT technology. 25 Overall, double emulsion solvent evaporation and spary drying are the most widely used methods for antigen loading in PLGA particles in laboratory scale. However, it is worth mentioning that for movement from laboratory to market it is necessary to consider GMP requirements and also consistency in particle preparation that can be assured by novel methods such as microfluidic approaches and PRINT technology.…”

mentioning

confidence: 99%

Peptide/protein vaccine delivery system based on PLGA particles

Allahyari

Mohit

2015

Human Vaccines & Immunotherapeutics

173

109

View full text Add to dashboard Cite

Due to the excellent safety profile of poly (D,L-lactide-co-glycolide) (PLGA) particles in human, and their biodegradability, many studies have focused on the application of PLGA particles as a controlled-release vaccine delivery system. Antigenic proteins/peptides can be encapsulated into or adsorbed to the surface of PLGA particles. The gradual release of loaded antigens from PLGA particles is necessary for the induction of efficient immunity. Various factors can influence protein release rates from PLGA particles, which can be defined intrinsic features of the polymer, particle characteristics as well as protein and environmental related factors. The use of PLGA particles encapsulating antigens of different diseases such as hepatitis B, tuberculosis, chlamydia, malaria, leishmania, toxoplasma and allergy antigens will be described herein. The co-delivery of antigens and immunostimulants (IS) with PLGA particles can prevent the systemic adverse effects of immunopotentiators and activate both dendritic cells (DCs) and natural killer (NKs) cells, consequently enhancing the therapeutic efficacy of antigen-loaded PLGA particles. We will review co-delivery of different TLR ligands with antigens in various models, highlighting the specific strengths and weaknesses of the system. Strategies to enhance the immunotherapeutic effect of DCbased vaccine using PLGA particles can be designed to target DCs by functionalized PLGA particle encapsulating siRNAs of suppressive gene, and disease specific antigens. Finally, specific examples of cellular targeting where decorating the surface of PLGA particles target orally administrated vaccine to Mcells will be highlighted.

show abstract

mentioning

confidence: 99%

Peptide/protein vaccine delivery system based on PLGA particles

Allahyari

Mohit

2015

Human Vaccines & Immunotherapeutics

173

109

View full text Add to dashboard Cite

show abstract

“…This example highlights the role that the particle modulus can play in organ delivery. The highly versatile PRINT technology has been used to prepare NP vaccines that have been translated into an initial Phase I/IIa clinical trial for influenza (103). Fig.…”

Section: Organic Nanoparticles For Drug Deliverymentioning

confidence: 99%

Nanotechnologies for biomedical science and translational medicine

Heath

2015

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

In 2000 the United States launched the National Nanotechnology Initiative and, along with it, a well-defined set of goals for nanomedicine. This Perspective looks back at the progress made toward those goals, within the context of the changing landscape in biomedicine that has occurred over the past 15 years, and considers advances that are likely to occur during the next decade. In particular, nanotechnologies for health-related genomics and single-cell biology, inorganic and organic nanoparticles for biomedicine, and wearable nanotechnologies for wellness monitoring are briefly covered.nanotechnology | biotechnology | nanomedicine

show abstract

“…Active components can be varied widely as well and include oligonucleotides, 9-11 RNA, 12,13 polysaccharides, proteins, 6,13,14 and small molecules 11,[15][16][17] that can serve as antigens or immunomodulators. The particle matrix can be composed entirely of active components or selective inert materials such as poly(lactic-co-glycolic) acid (PLGA), 6 or polyethylene glycol (PEG) hydrogels 7 that serve as bulking agents to reduce costs. As will be shown in the examples below, it is possible to formulate multiple materials together within the same particle, including poorly miscible compounds.…”

Section: Print (Particle Replication In Non-wetting Templates) Platformmentioning

confidence: 99%

Engineered PRINT^® nanoparticles for controlled delivery of antigens and immunostimulants

Beletskii

Galloway

Rele

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Particle replication in non-wetting templates (PRINT) is a novel nanoparticle platform that provides compositional flexibility with the ability to specify size and shape in formulating vaccines. The PRINT platform also offers manufacturing and cost advantages over traditional particle technologies. Across multiple antigen and adjuvant formulations, robust antibody and cellular responses have been achieved using PRINT particles in mouse models. Preclinical studies applying PRINT technology in the disease areas of influenza, malaria, and pneumonia are described in this commentary. The proof of principle studies pave the way toward significant cost-effective solutions to global vaccine supply needs.

show abstract

Development of a nanoparticle-based influenza vaccine using the PRINT® technology

Cited by 80 publications

References 32 publications

Peptide/protein vaccine delivery system based on PLGA particles

Peptide/protein vaccine delivery system based on PLGA particles

Nanotechnologies for biomedical science and translational medicine

Engineered PRINT^® nanoparticles for controlled delivery of antigens and immunostimulants

Contact Info

Product

Resources

About

Development of a nanoparticle-based influenza vaccine using the PRINT® technology

Cited by 80 publications

References 32 publications

Peptide/protein vaccine delivery system based on PLGA particles

Peptide/protein vaccine delivery system based on PLGA particles

Nanotechnologies for biomedical science and translational medicine

Engineered PRINT® nanoparticles for controlled delivery of antigens and immunostimulants

Contact Info

Product

Resources

About

Engineered PRINT^® nanoparticles for controlled delivery of antigens and immunostimulants